Dublin - Research and Markets (http://www.researchandmarkets.com/research/9a53d8cb/biologics_market_i) has announced the addition of Frost & Sullivan's new report "Biologics Market in Brazil" to their offering.
Biologic drugs are significantly advancing the treatment of serious diseases such as Alzheimer's, Rheumatoid Arthritis, different types of cancer (for example, breast and renal cancers as well as leukemia), Multiple Sclerosis, Lupus, and Leprosy.
Discovering, manufacturing, and testing biologic drugs can sometimes take more than ten times the cost and five times the development time of synthetic drugs. Because they are made by living organisms, the manufacturing process for biologic drugs requires a high degree of technology to stabilize complex molecular structures. Any small deviation in the production process can change the effect of the drug.
Thus, regulations regarding biologic drugs must be strict. Brazil has already taken steps to establish a highly regulated market given December 2011's regulation changes, but the country is still far from European regulation levels.
Public programs, such as the National List of Essential Medicines (RENAME) and Farmacia Popular, are important drivers of the market. For some biologic segments, such as insulin and blood agents, the government provides the population with free biologic drugs, which ensures demand because most of the population cannot afford the expensive costs of biologics without this assistance.
The Brazilian market is dominated by big multinational companies. Their brands and drugs are already established on the market, and in all segments they have the largest shares.
Local production for biologics is still very low. Of the 26 main brands of biologics, only 8 are Brazilian, and their products do not have the same market penetration as the multinational companies.
For market share in Brazilian biologics, Roche, Novo Nordisk, and Eli Lilly are the top three vendors.
Monoclonal antibodies are the most lucrative segment, with revenue of $767.7 million in 2010 and a CAGR of 25.0 percent until 2017.
About This Report:
This research service considers the biologics market in Brazil. It covers the market's move toward greater regulation and outlines the impact of specific patent expirations. An analysis of monoclonal antibodies, blood factors, insulin, filgrastim, interferon, growth hormones, and erythropoietin is provided. This service also highlights key market drivers and restraints in addition to breaking down the current and forecasted competitive scenario. The base year of the study is 2010, and the forecast period is 2011 to 2017.
Key Topics Covered:
- Executive Summary
- Introduction to Biologics
- The Global Biologics Market
- The Brazilian Biologics Market
- Competitive Scenario
- Key Market Segments
- Regulatory Scenario
- Profile of Key Industry Participants
For more information visit http://www.researchandmarkets.com/research/9a53d8cb/biologics_market_i
Source: Frost & Sullivan